AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$PLSE

Teplitsky Liane Rae purchased $100K of PLSE

Teplitsky Liane Rae (Chief Operating Officer) purchased 2,070 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $48.29 ($48.24–$48.35) across 2 trades over 2026-08-26 to 2026-08-28.

Original reporting
SEC EDGAR · Teplitsky Liane Rae
Published Aug 28, 2026, 11:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PLSE
Neutral
medium confidence
Mentioned
$PLSE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLSENeutralLow
01

Why it matters

The disclosed purchase is modest and unlikely to move the stock significantly, but it adds to the insider activity record.

02

Market read

Limited relevance; adds a data point to insider activity monitoring.

03

What to watch

Potential upcoming clinical trial milestones that may have prompted the insider to increase stake.

Relevance 4/10Novelty 3/10Timing: reported after market close on 2026-08-28

Background

Form 4 filings disclose insider transactions; investors monitor them for signals of insider confidence.

Company-level read

Ticker impact

$PLSENeutralMedium confidence
Context

COO Teplitsky Liane Rae bought 2,070 shares of Pulse Biosciences for $99,965, a direct insider purchase disclosed on Form 4.

Expected impact

Minor upward pressure, likely within normal volatility range.

Evidence & confidence

Purchase amount is under $100k and represents a tiny fraction of float; while insider buying is positive, the scale does not suggest a material shift.

Market effects

Sector

Minimal effect on biotech sector; typical insider activity.

Regional

No regional impact.

Global

Not globally relevant.

Counterpoint

What could challenge this read

The purchase could be a routine compensation exercise rather than a confidence signal.

Key entities

  • Company
    Pulse Biosciences, Inc.

    Biotech firm developing cell-based therapies.

  • Person
    Teplitsky Liane Rae

    Chief Operating Officer of Pulse Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PLSE insider trading history →

Related articles

OCT 8
$PLSEMedAI 8/10

How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.

simplywall.st3 min
OCT 7
$PLSEMedAI 8/10

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation…

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California , October 7, 2026 — Puls

SEC EDGAR 8-K2 min
OCT 7
$PLSELowAI 8/10

Pulse Biosciences completes enrollment in cardiac ablation study

Pulse Biosciences (PLSE) completed enrollment in its NANOPULSE-AF Study for treating atrial fibrillation, hitting its 164-patient target three months early. The study evaluates the safety and effectiveness of its nPulse Cardiac Catheter System. Primary endpoints will be assessed at six and 12 months post-ablation. The company plans to share updates and present data at future conferences.

investing.com1 min
OCT 6
$PLSEMed

Canaccord raises Pulse Biosciences stock price target on tech potential

Canaccord raised its price target on Pulse Biosciences (PLSE) to $58 from $43, maintaining a Buy rating. The stock has surged 87.5% since Canaccord initiated coverage and 268% year-to-date, with a $3.6B market cap. The firm cited the company's nanosecond pulse field ablation platform and clinical progress. Pulse also announced an equity distribution agreement with Mizuho Securities for up to $85M in common stock sales.

investing.com2 min
SEP 15
$PLSEMedAI 8/10

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic…

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse ™ Vybrance ™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed

SEC EDGAR 8-K1 min